Barclays
EXAS

Barclays’s Exact Sciences EXAS Stock Holding History

Barclays’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-191,743
Closed -$19.5M – 5168
2025
Q4 		$19.5M Sell
191,743
-101,033
-35% -$8.11M ﹤0.01% 1270
2025
Q3 		$16M Sell
292,776
-153,865
-34% -$7.69M ﹤0.01% 1356
2025
Q2 		$23.7M Buy
446,641
+139,954
+46% +$7.11M 0.01% 1036
2025
Q1 		$13.3M Buy
306,687
+127,306
+71% +$6.45M ﹤0.01% 1234
2024
Q4 		$10.1M Sell
179,381
-30,391
-14% -$1.89M ﹤0.01% 1564
2024
Q3 		$14.3M Sell
209,772
-95,512
-31% -$5.39M ﹤0.01% 1244
2024
Q2 		$12.9M Buy
305,284
+78,345
+35% +$4.31M ﹤0.01% 1091
2024
Q1 		$15.7M Sell
226,939
-14,677
-6% -$928K 0.01% 1123
2023
Q4 		$17.9M Buy
241,616
+41,529
+21% +$2.72M 0.01% 1116
2023
Q3 		$13.6M Buy
200,087
+17,243
+9% +$1.46M 0.01% 878
2023
Q2 		$17.2M Sell
182,844
-18,241
-9% -$1.42M 0.01% 777
2023
Q1 		$13.6M Sell
201,085
-89,865
-31% -$5.78M 0.01% 1030
2022
Q4 		$14.4M Sell
290,950
-9,787
-3% -$400K 0.01% 1034
2022
Q3 		$9.77M Buy
300,737
+49,589
+20% +$2.04M 0.01% 866
2022
Q2 		$9.89M Buy
251,148
+45,576
+22% +$2.44M 0.01% 1018
2022
Q1 		$14.4M Sell
205,572
-13,754
-6% -$1.01M 0.01% 798
2021
Q4 		$17.1M Sell
219,326
-5,369
-2% -$474K 0.01% 1008
2021
Q3 		$21.4M Buy
224,695
+92,388
+70% +$9.75M 0.01% 852
2021
Q2 		$16.4M Buy
132,307
+41,628
+46% +$4.97M 0.01% 980
2021
Q1 		$11.9M Buy
90,679
+8,200
+10% +$1.12M 0.01% 1006
2020
Q4 		$10.9M Buy
82,479
+11,246
+16% +$1.36M 0.01% 1126
2020
Q3 		$7.26M Buy
71,233
+441
+0.6% +$38.1K ﹤0.01% 1181
2020
Q2 		$6.15M Sell
70,792
-33,838
-32% -$2.7M ﹤0.01% 1218
2020
Q1 		$6.07M Sell
104,630
-60,239
-37% -$4.89M ﹤0.01% 1315
2019
Q4 		$15.2M Buy
164,869
+41,721
+34% +$3.67M 0.01% 1109
2019
Q3 		$11.1M Buy
123,148
+77,188
+168% +$8.79M 0.01% 1220
2019
Q2 		$5.42M Sell
45,960
-56,003
-55% -$5.64M ﹤0.01% 1795
2019
Q1 		$8.83M Sell
101,963
-11,161
-10% -$950K 0.01% 1302
2018
Q4 		$7.14M Buy
113,124
+75,419
+200% +$5.18M 0.01% 1353
2018
Q3 		$2.98M Sell
37,705
-210,563
-85% -$13.7M ﹤0.01% 2418
2018
Q2 		$14.8M Buy
248,268
+138,137
+125% +$7.43M 0.01% 969
2018
Q1 		$4.44M Buy
110,131
+30,602
+38% +$1.49M ﹤0.01% 1730
2017
Q4 		$4.18M Buy
79,529
+76,603
+2,618% +$4.09M ﹤0.01% 1805
2017
Q3 		$137K Sell
2,926
-6,962
-70% -$280K ﹤0.01% 4708
2017
Q2 		$350K Sell
9,888
-9,914
-50% -$306K ﹤0.01% 3867
2017
Q1 		$468K Sell
19,802
-22,981
-54% -$455K ﹤0.01% 3462
2016
Q4 		$572K Buy
42,783
+33,274
+350% +$537K ﹤0.01% 3254
2016
Q3 		$176K Sell
9,509
-37,578
-80% -$662K ﹤0.01% 4063
2016
Q2 		$577K Buy
47,087
+19,108
+68% +$144K ﹤0.01% 3093
2016
Q1 		$168K Buy
27,979
+17,658
+171% +$113K ﹤0.01% 3959
2015
Q4 		$93K Buy
10,321
+716
+7% +$6.66K ﹤0.01% 4441
2015
Q3 		$165K Sell
9,605
-34,925
-78% -$802K ﹤0.01% 4280
2015
Q2 		$1.29M Buy
44,530
+25,049
+129% +$629K ﹤0.01% 2652
2015
Q1 		$427K Buy
19,481
+9,164
+89% +$232K ﹤0.01% 3744
2014
Q4 		$279K Sell
10,317
-141,181
-93% -$3.44M ﹤0.01% 4371
2014
Q3 		$2.88M Buy
151,498
+149,562
+7,725% +$2.74M ﹤0.01% 2325
2014
Q2 		$32K Sell
1,936
-47,675
-96% -$656K ﹤0.01% 6235
2014
Q1 		$694K Buy
49,611
+12,081
+32% +$163K ﹤0.01% 3625
2013
Q4 		$413K Buy
37,530
+25,058
+201% +$287K ﹤0.01% 4287
2013
Q3 		$138K Buy
12,472
+1,918
+18% +$24.6K ﹤0.01% 5362
2013
Q2 		$147K Buy
+10,554
New +$115K ﹤0.01% 5468

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Barclays's EXAS Position: Q1 2026 in Review

Barclays sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 191,743 shares — an estimated $19.5M sold.

Barclays first reported a position in EXAS in Q2 2013 and held it in 51 quarters. The position peaked at $23.7M in Q2 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Barclays reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 191,743 Exact Sciences shares in Q1 2026, an estimated $19.5M.
  • Barclays first reported a position in Exact Sciences in Q2 2013 and held it in 51 quarters.
  • Barclays's Exact Sciences position peaked at $23.7M in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.